
    
      Participants will be randomly assigned in a 1:1 ratio to receive CBD or matching Placebo as
      an add-on to antipsychotic medication in an 8 week double blind trial. In this study,
      Cannabidiol Oral Solution (CBD) product will be used. This product is manufactured and
      supplied by GW Pharmaceuticals. The formulation is a 100 mg/mL solution. The CBD compound
      will be dosed at 1000mg/day administered in two divided doses. The dose of CBD was selected
      based on previous controlled trials that demonstrate the efficacy of CBD in patients with
      schizophrenia.

      The maximum duration of the study from screening to follow up of outcomes and adverse events
      will be approximately 8 weeks. Participants will receive either the CBD or placebo within
      this eight.weeks and will also complete pre-treatment, midpoint (week 4) and post-treatment
      testing (week 8).
    
  